Chocolate agar media rev 4.indd

TECHNICAL DATA SHEET #230 REV. 4
CHOCOLATE AGAR MEDIA
(GC MEDIA BASE)
SELECTIVE AND NONSELECTIVE
PRODUCTS:
Plated, Tubed, and Bottled Media
:a
P1950, P3600 (JEMBEC), P3602 (Pill-Pocket) Modifi ed, Modifi ed Thayer-Martin Agar (MMTM) Chocolate/Modifi ed Martin-Lewis Media (MMLM) PURPOSE:
Chocolate Agar media are used for the isolation and cultivation of fastidious microorganisms, primarily pathogenic Neisseria and
Haemophilus species.
PRINCIPLE:
Pathogenic Neisseria and Haemophilus species, among other fastidious microbes, will grow only in the presence of certain
nutrients which can be found in Chocolate Agar. Originally, red blood cells were added to a melted nutrient base and heated to
approximately 85°C which lysed the red blood cells, releasing into the base media hemoglobin and other nutrients present in lysed
blood.9 Now these ingredients, hemoglobin and XV Factor Enrichment, are supplements added to the nutrient GC Base media.
XV Factor Enrichment is rich in vitamins, additional cofactors, and amino acids. GC Media base consists of a complementary
mixture of animal and vegetable peptones, cornstarch, and salts and was discovered as a result of the studies done by Johnston13
in 1945.
Scientists, including Thayer, Martin, and Lester,1,6-8,10,11,12,15,16 further modifi ed the Chocolate Agar formula by adding antibiotics and increasing the dextrose and agar concentrations, resulting in selective media used for the isolation of pathogenic members of the family Neisseriaceae from clinical specimens with large numbers of mixed normal fl ora. Vancomycin inhibits gram-positive bacteria; colistin inhibits gram-negative bacteria; nystatin inhibits some yeasts; and trimethoprim inhibits the growth of swarming Proteus species.
Modifi cations continued to evolve due to discoveries found in the clinical setting; some strains of Candida albicans inhibit the growth of some N. gonorrhoeae and nystatin proved ineffective in inhibiting C. albicans.4,14 The antifungal agent, anisomycin, was substituted for nystatin and has proved effective (Martin-Lewis Media). The concentration of vancomycin was increased from 3 mcg/ml to 4 mcg/ml for greater inhibition of gram-positive bacteria6 but the discovery of a signifi cant number of N. gonorrhoeae being susceptible to low concentrations of vancomycin has lead to lowering the concentration back to 2 mcg/ml (Modifi ed Martin-Lewis Media). Modifi cations continued with the replacement of anisomycin with amphotericin B, and the addition of lincomycin to the formula.
In addition to discovering media that would assist in the effective recovery of pathogenic Neisseriaceae, transport systems were developed to improve the recovery of gonococci which are very susceptible to adverse environmental conditions, to delays in transport, and which may be present in clinical specimens only in small numbers. The JEMBEC* (John E. Martin Biological Environmental Chamber) and the Pill-Pocket Systems, consisting of selective media, CO -generating tablets, and small gas-im- permeable plastic bags also aid in the recovery of gonococci. The chambers contain an inner well molded into the plate in which a CO -generating tablet (sodium bicarbonate and citric acid) is inserted. Moisture activates the tablet which then provides a CO atmosphere conducive for the growth of gonococci.
Note: Modifi ed, Modifi ed Thayer-Martin Media (MMTM) and Martin Lewis Media (MLM) have the same formula and will demonstrate 27120 SW 95th Avenue • Wilsonville, OR 97070 • 800.547.0659 TECHNICAL DATA SHEET #230 REV. 4
*registered trademark of Miles Scientifi c FORMULAS:
Approximate, per liter of deionized fi ltered water.
(1) Chocolate Agar with Enrichment:
Peptic Digest of Animal Tissue . 7.5 gPancreatic Digest of Casein . 7.5Cornstarch . 1.0 Dipotassium Phosphate . 4.0Sodium Chloride . 5.0Agar . 14.5Hemoglobin . 10.0XV Factor Enrichment . 10.0 ml Final pH 7.2 ± 0.2 at 25°C (2) GC Media without Hemoglobin:
Same
(1) above without hemoglobin
(3) Selective
(1) above with the addition of 1.5 g of dextrose and:
Vancomycin Amphotericin Colistin Trimethoprim Nystatin Lincomycin Agar
(4) Thayer Martin Vancomycin:
Same
(1) above with the addition of 12.5 ml TMV Enrichment
PRECAUTIONS:*
For in vitro diagnostic use. Observe approved biohazard precautions.
Storage: Upon receipt store at 2-8°C away from direct light. Media should not be used if there are signs of contamination,
deterioration (shrinking, cracking, or discoloration), or if the expiration date has passed.
Limitations: Some strains of gonococci, usually arginine, hypoxanthine, uracil, (AHU) strains, are inhibited by vancomycin, and
other gonococci are inhibited by trimethoprim. These strains can grow on nonselective Chocolate Agar media. See “New York
City Media, Modifi ed,” as an additional option for a selective media.
Normal fl ora of the pharynx, female genital tract, and the rectum grow more rapidly than gonococci and can inhibit gonococcal growth.
Certain gram-positive cocci will grow through on selective media incubated in excess of 48 hours.
Chocolate Agar with Enrichment will not support the growth of all fastidious organisms; some organisms require further enrichment in order to be recovered from clinical specimens.
PROCEDURE:*
Specimen Collection:
Temperature and CO requirements of some fastidious organisms require that the processing of specimens
be rapid; plated specimens for the recovery of gonococci and meningococci should be incubated immediately upon collection. Information on specimen collection is found in standard reference material. In general, specimens should be protected from extreme heat, cold, or desiccation and delivered to the microbiology laboratory without delay. If delay is unavoidable, use of a buffered holding media such as Amies Charcoal has proven effective for the recovery of most microorganisms. The recovery of gonococci, because they are very susceptible to adverse environmental conditions, has been more effective with the use of biological environment chambers inoculated directly at the patient care area.
27120 SW 95th Avenue • Wilsonville, OR 97070 • 800.547.0659 TECHNICAL DATA SHEET #230 REV. 4
Method of Use, Chocolate Agar Media: Prior to inoculation, the media should be brought to room temperature. Inoculate the
media by rolling a swab onto the agar, making certain all areas of the swab touch the agar, or by dropping 1-2 drops of a liquid
specimen the size of a 25 cent piece onto the media. Using standard microbiological procedures, streak the inoculum so as
to obtain isolated colonies. Incubate at 35°C in 5-10% CO for 18-72 hours. Examine daily for growth of possible pathogens.
Perform Gram stains and biochemical and/or serological tests to identify defi nitively the microbes cultured. See appropriate references for further details.
Method of Use, Selective Chocolate Agar Media: Prior to inoculation, the media should be brought to room temperature.
Heavily inoculate the selective media by rolling the swab across the plate, forming a large “Z” pattern. Streak the plate in order
to obtain isolated colonies. Incubate as above.
Method of Use, Transport Systems:
Biological Environment Chambers (JEMBEC, Pill-Pocket):
After inoculation, place a CO -generating tablet in the molded
well. Replace the lid and place the chamber into the gas-impermeable plastic bag and securely close the bag. Allow the moisture from the media to activate the tablet and invert the plate after the pill is moistened.
For maximum recovery using nutritive transport systems, incubate at 35°C for 18-24 hours before delivering to the laboratory. Upon arrival at the microbiology laboratory, examine the transport plates for growth; continue to incubate at 35°C in 5-10% CO for a total of 72 hours, as is done for routine selective media. Examine daily for morphologically typical colonies and presump-tively or defi nitively identify microbial growth with further biochemical and/or serological tests. See appropriate references for further details.
Interpretation: Chocolate Agar media, when properly inoculated with a specimen, will exhibit isolated colonies. N. gonorrhoeae
grows as a small, mucoid colony, colorless to grayish-white, while N. meningitidis usually forms a larger, bluish-gray mucoid
colony. In both cases the colonies are raised, fi nely granular, glistening, and convex. A Gram stain should be performed for
any colonies appearing to be Neisseria and tested for oxidase production. Testing for carbohydrate utilization and/or serological
tests need also to be performed.
Haemophilus species are strict parasites, growing only in the presence of certain growth factors, X (hemin, hemoglobin) or V (coenzyme 1, NAD), or both. Microscopic examination shows small, usually pleomorphic, gram-negative rods, coccobacilli, or threadlike organisms. Haemophilus infl uenzae, the major pathogen of this genus, requires both X and V factors. Growth appears on Chocolate Agar in 18-24 hours as small, colorless, transparent, moist colonies with a distinct “mousey” odor. A Gram stain should be performed for any colonies appearing to be Haemophilus, and examined for hemolytic reactions, and biochemically and/or serologically tested.
Material Required but Not Provided: Standard microbiological supplies and equipment commonly found in a microbiological
laboratory are not provided.
QUALITY CONTROL:*
Media Used:

Microorganisms Used (ATCC #):
Expected Results:
Neisseria gonorrhoeae (43070, 49226, 43069) Staphylococcus epidermidis (12228) User Quality Control: Check for signs of contamination and deterioration and test the ability of the Chocolate Agar media,
selective and nonselective, to support the growth of Neisseria gonorrhoeae as defi ned by the regulatory agencies. Chocolate
Agar media should appear fi rm, opaque, and chocolate brown in color with the exception of GC Media without Hemoglobin, which
should appear fi rm, translucent, and light tan in color.
BIBLIOGRAPHY:
1. Faru, Y. C., et al., Health Lab. Scien., 10:55, 1973.
27120 SW 95th Avenue • Wilsonville, OR 97070 • 800.547.0659 TECHNICAL DATA SHEET #230 REV. 4
2. Forbes, B. A., et al., Bailey and Scott’s Diagnostic Microbiology, 12th ed., C. V. Mosby, St. Louis, 2007.
3. Hipp, S. S., et al., Appl. Microbiol., 27:192, 1974.
4. Hipp, S. S., et al., J. Clin. Pathol., 1:476, 1975.
5. Johnson, J. Venereal Dis. Inform., 26:239, 1945.
6. Martin, J. E., et al., Appl. Microbiol., 27:802, 1974.
7. Martin, J. E., and A. Lester, HSMHA Health Reports, 86:30, 1971.
8. Martin, J. E., and J. E. Lewis, Publ. Health Lab., 35:33, 1977.
9. Murray, P.R., et al., Manual of Clinical Microbiology, 9th ed., American Society for Microbiology, Washington, D.C., 10. Odegard, K., Acta Path. Scand., Section B, 79:545-548, 1971.
11. Personal Communication, USHEW, CDC, Atlanta, 1979.
12. Riddell, R. H., and A. C. Buck, J. Clin. Pathol., 23:481-483, 1970.
13. Robinson, R. Q., Memorandum, USHEW, CDC, January 2, 1975.
14. Seth, A., Br. J. Ven. Dis., 46:201-202, 1970.
15. Thayer, J. D., and J. E. Martin, Publ. Health Reports, 79:49, 1964.
16. Thayer, J. D., and J. E. Martin, Publ. Health Reports, 81:559, 1966.
*For more detailed information consult appropriate references.
bioMérieux, Inc.
Data #230Revision Date: May 2009 27120 SW 95th Avenue • Wilsonville, OR 97070 • 800.547.0659

Source: http://muller.ch.free.fr/bts-abm/images/documents/microbiologie2/chocolat.pdf

D:\lichtkegel\ges. angew. philo\literaturliste.wpd

Literatur zur philosophischen Praxis ACHENBACH Gerd: Philosophische Praxis, Köln 19872 BADURA Jens: Die Suche nach Angemessenheit. Praktische Philosophie als ethische Beratung,BAUSCH Thomas / KLEINFELD Annette / STEINMANN Horst (Hg.): Unternehmensethik in derBERG Melanie: Philosophische Praxen im deutschsprachigen Raum. Eine kritische Bestands-BIRNBACHER Dieter / KROHN Dieter (Hg.): Das so

Microsoft word - counseling info for printing pdfs.doc

Albuterol; Ipratropium inhalation aerosol and solution What are albuterol; ipratropium inhalation aerosol and solution? ALBUTEROL; IPRATROPIUM (Combivent®, DuoNeb™) is a combination of bronchodilators, which are medicines that open up your air passages and make breathing easier. The combination is used for patients with lung problems such as chronic bronchitis and emphysema. This medicine cont

© 2010-2018 Modern Medicine